UNI-494 was well-tolerated as a single dose up to 160 mg and in multiple doses at 40 mg twice-a-day ... Kidney Week 2024 ...

Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025- - Commercial Planning in Progress for 2025 Launch - - Late Breaker Poster Presentation ...

Adagene (ADAG) announced data at the SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024. The two poster presentations ...

Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

The combination of sitravatinib, nivolumab, and ipilimumab appears safe and active in patients with advanced clear cell renal cell carcinoma (ccRCC), according to research presented in a poster at ...

Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...

The poster will be presented at the American Heart Association ... The model also demonstrated that the two doses selected for the APEX phase 2 study, 300 mg every two weeks (Q2W) and 300 mg every ...

Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected ...

over 28 days 67% of study participants lost 5% or more of their baseline body weight at the highest dose of 740 mg once-daily ...

Researchers provided recommendations for managing adverse events in patients with renal cell carcinoma receiving cabozantinib and nivolumab.